Ann: Change of Director's Interest Notice - Paul Anderson, page-14

Sorry, but you are so wrong on them needing a capital raise in the near future. Have you looked at the cash burn? The money on hand?

Again, if you are struggling to predict forward business metrics yourself, take a look at Veritas, take a look at their cash use forecasts (a little conservative for my liking, but useful professional presentation). OCC will likely be going cash flow positive on the BH deal and likely forthcoming Remplir revenues, not milking the market for more cash, as it so often has in the past - hence Paul buying (for once he will honestly agree no more raises).

Feel sorry for you HD. You were patient for so long, then appear to have lost that patience just as they are finally commercialising their products.

Have a look at Amgen in the US (not that I am remotely suggesting OCC will be that big). It took 20 years to become a $1 billion company. Then in the next 20 years it became a $100 billion company. Apply a massive degree of unpredictability on success, but ATI really has the potential to make OCC a global mainstay in Orthopedics with some serious revenues likely via more big Pharma partnerships.

Orthowho? Someone very funnily mocked me before on here. They were right, hence potential returns are huge on this one, and the risk of execution very much reduced by the BH deal.